Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583878 · ClinicalTrials.gov registry record
FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
A clinical trial of Pulmonary Embolism and Deep Venous Thrombosis, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- 115
- Enrollment target
- 14
- Study locations
NCT04583878: Active study of Pulmonary Embolism and Deep Venous Thrombosis, sponsored by University of Texas Southwestern Medical Center.
NCT04583878 is a study of Pulmonary Embolism and Deep Venous Thrombosis that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 115 participants, below the 3,056-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04583878, a study of Pulmonary Embolism and Deep Venous Thrombosis, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 115 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a multi-center prospective cohort study of patients with first-episode deep venous thrombosis and pulmonary embolism.
Primary Outcome
Measured objectively by peak oxygen uptake (VO2) as a percent predicted based on ml/min/kg of lean body mass during cardiopulmonary exercise testing (CPET)
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood draw (Visit 1)
- DIAGNOSTIC_TEST Blood draw (Visits 2 and 3)
Study Locations (14)
Texas
- UT Southwestern Medical Center / Children's Medical Center - Dallas
- Cook Childrens Medical Center - Fort Worth
- Texas Children's Hospital - Houston
Ohio
- Cincinnati Childrens Hospital - Cincinnati
- Nationwide Children's Hospital - Columbus
Arkansas
- Arkansas Childrens Research Institute (ACRI) - Little Rock
Florida
- Johns Hopkins All Childrens Hospital - St. Petersburg
Georgia
- Emory University / Children's Heathcare Atlanta - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Michigan
- Central Michigan University - Mount Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2026-12 |
What the registry record for NCT04583878 still lists
NCT04583878 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 3,056-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which Blood draw (Visit 1) is the first listed.
NCT04583878 lists 14 locations in 11 states (Texas, Ohio, Arkansas).
Frequently Asked Questions
What is clinical trial NCT04583878 about?
NCT04583878 is a clinical study titled "FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease". This is a multi-center prospective cohort study of patients with first-episode deep venous thrombosis and pulmonary embolism.
What is the current status of trial NCT04583878?
This trial is currently active not recruiting. The enrollment target is 115 participants. The study started on 2020-12-22. Estimated completion is 2026-12.
What conditions does trial NCT04583878 study?
This clinical trial studies the following conditions: Pulmonary Embolism, Deep Venous Thrombosis.
What interventions are being tested in trial NCT04583878?
The interventions under investigation include: Blood draw (Visit 1) (DIAGNOSTIC_TEST), Blood draw (Visits 2 and 3) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04583878?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04583878 being conducted?
This trial has 14 study locations across Arkansas, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04583878's enrollment target sits among peer trials
115 34th of 48 higher than 15 of 48 other Pulmonary Embolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
The PERSEVERE Study
RECRUITING · NA
-
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
RECRUITING
-
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI